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Abstract 
Background: Herpes zoster (HZ, shingles) is a frequent medical condition which may 
severely impact the quality of life of affected patients. Different therapeutic approaches to 
treat acute HZ are available.  
Objective: The aim of this European project was the elaboration of a consensus-based 
guideline on the management of patients who present with HZ, considering different patient 
populations and different localisations. This interdisciplinary guideline aims at an 
improvement of the outcomes of the acute HZ management concerning disease duration, 
acute pain and quality of life of the affected patients and at a reduction of the incidence of 
PHN and other complications.  
Methods: The guideline development followed a structured and predefined process, 
considering the quality criteria for guidelines development as suggested by the AGREE II 
instrument. The steering group was responsible for the planning and the organisation of the 
guideline development process (Division of Evidence based Medicine, dEBM). The expert 
panel was nominated by virtue of clinical expertise and/or scientific experience and included 
experts from the fields of dermatology, virology/infectiology, ophthalmology, otolaryngology, 
neurology and anaesthesiology. Recommendations for clinical practice were formally 
consented during the consensus conference, explicitly considering different relevant aspects. 
The guideline was approved by the commissioning societies after an extensive internal and 
external review process.   
Results: In this first part of the guideline, diagnostic means have been evaluated. The expert 
panel formally consented recommendations for the management of patients with (suspected) 
HZ, referring to the assessment of HZ patients, considering various specific clinical 
situations. 
Conclusion: Users of the guideline must carefully check whether the recommendations are 
appropriate for the context of intended application. In the setting of an international guideline, 
it is generally important to consider different national approaches and legal circumstances 
with regards to the regulatory approval, availability and reimbursement of diagnostic and 
therapeutic interventions.  
Keywords: Clinical practice guideline, consensus statements, European guideline, herpes 
zoster, immunocompromized patients, postherpetic neuralgia, pregnancy, Ramsay-Hunt-
Syndrome, recommendations, shingles, zoster ophthalmicus, zoster oticus 
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Disclaimer 
Guidelines are intended to assist clinicians in standardized clinical situations. The final 
judgement with regards to the selection and administration of therapeutic interventions lies 
within the responsibility of the treating physician and must be individualized in light of all 
presenting circumstances. Users of the guideline must carefully check whether the 
recommendations are complete, correct, up-to-date and appropriate considering approval 
status, dosing regimes, mode of application, contra-indications, adverse effects and drug 
interactions. European guidelines are intended to be adapted to national circumstances (e.g. 
regarding regulatory approval, availability, reimbursement issues).  
 
Clinical background / Introduction  
Herpes zoster (HZ, shingles) and zoster-associated pain (ZAP) result from a reactivation of 
varicella zoster viruses (VZV) persisting in the sensory nerve ganglia after the primary 
infection with VZV.1 Primary infection usually occurs during childhood and leads to varicella 
(chickenpox), characterized by a generalized rash, during which a latent infection in sensory 
neurons in the dorsal root ganglia (DRG) along the entire neuroaxis is established. Decades 
later, when virus-specific cellular immunity wanes during aging2 or as a result of 
immunosuppression, a reactivation of the latent infection with replication of VZV in one or 
more DRG causes HZ. Following reactivation, virions are carried antidromically through the 
axons via the microtubular system. Having arrived at the intra-epidermal nerve endings and 
the perifollicular neural network, viral replication is induced in the epidermal and/or 
infundibular keratinocytes. Classically, virus replication is associated with alterations in 
keratinocytic differentiation, ressembling a pattern of gene expression associated with 
blistering and vesicle formation.3 This process is associated with histological evidence of 
cytopathic changes, including giant cell and syncytia formation, eosinophilic nuclear 
inclusions and ultimately apoptosis. 
With an incidence rate of 2-3/1000 person-years in the general population4, 5 and of 7-
10/1000 person-years after the age of 50 years,6, 7 HZ is a frequent medical condition. The 
rate of hospitalization due to an episode of HZ is reported to be around 10/100,000/year in 
Spain8 and the impact of the disease on the patients’ quality of life may be severe9, 10. The 
incidence is strongly correlated with age6, 7 and immunodeficiency11. A frequent complication 
of HZ, often difficult to treat, is the postherpetic neuralgia (PHN).1 Generally, HZ-associated 
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mortality is low in European countries, but was shown to reach up to 19.5/100,000 in specific 
age groups (>95 year-olds).12  
The recently available vaccine for the prevention of HZ was shown to reduce the incidence of 
HZ by 51%13, 14, but insufficient evidence is available to depict a reduction of the incidence of 
PHN beyond the reduction of the HZ incidence15. As life time prevalence of HZ episodes for 
unvaccinated 85 year-olds is estimated to be around 50%1, the incidence of HZ in vaccinated 
populations remains considerable. 
 
Scope, purpose and methods 
The quality criteria for guidelines development as suggested by the Appraisal of Guidelines 
Research and Evaluation (AGREE II) Instrument16 were incorporated into the development of 
the guideline. Detailed information on the scope, purpose and methods is reported in the 
methods report (online supplement). 
Five strengths of recommendations were differentiated, expressed by wording and symbols 
(strong recommendation in favour, ↑↑ / weak recommendation in favour, ↑ / no 
recommendation, 0 / weak recommendation against, ↓ / strong recommendations against, 
↓↓)17. Table 1 shows wording, symbols and implications of each strength of recommendation. 
The percentage of agreement among the guideline’s expert panel was noted and reported 
(≥50%, ≥75%, ≥90%) for each recommendation.  
Table 1: Strength of recommendation - wording, symbols and implications (modified from Andrews et 
al., 201317) 
Strength  Wording  Symbols  Implications 
Strong 
recommendation for 
the use of an 
intervention 
“We recommend 
…”  
↑↑ We believe that all or almost all informed people would 
make that choice. Clinicians will have to spend less time 
on the process of decision making, and may devote that 
time to overcome barriers to implementation and 
adherence. In most clinical situations, the 
recommendation may be adopted as a policy. 
Weak 
recommendation for 
the use of an 
intervention 
“We suggest …” ↑ We believe that most informed people would make that 
choice, but a substantial number would not. Clinicians 
and health care providers will need to devote more time 
on the process of shared decision making. Policy makers 
will have to involve many stakeholders and policy 
making requires substantial debate. 
No recommendation 
with respect to an 
intervention 
“We cannot make 
a 
recommendation 
with respect to 
…” 
0 At the moment, a recommendation in favour or against 
an intervention cannot be made due to certain reasons 
(e.g. no reliable evidence data available, conflicting 
outcomes, etc.) 
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Weak 
recommendation 
against the use of an 
intervention 
“We suggest 
against …” 
↓ We believe that most informed people would make a 
choice against that intervention, but a substantial 
number would not.  
Strong 
recommendation 
against the use of an 
intervention 
“We recommend 
against …” 
↓↓ We believe that all or almost all informed people would 
make a choice against that intervention. This 
recommendation can be adopted as a policy in most 
clinical situations. 
 
To reflect the recent state of the evidence, guidelines need to be continually updated. This 
guideline will expire after June 2021. Should important changes in the supporting evidence or 
in current practice occur in the meantime due to new available interventions, new important 
evidence or withdrawal of drug licensing, the information contained in the guideline will be 
outdated earlier.  
This first part of the guideline is devoted to diagnostic means in situations that occur in the 
management of patients who present with (suspected) HZ. This section of the guideline 
(background texts and recommendations) was drafted by A. F. Nikkels (Lead author), J. 
Breuer, G. E. Gross, R. Lapid-Gortzak, U. Pleyer, G. M. Verjans, P. Wutzler, A. M. Agius, T. 
M. Lesser, and J. Sellner. The final recommendations were formally consented within the 
expert panel of the guideline. 
 
General considerations 
Classically, HZ is a unilateral, dermatomal18-20 eruption, with skin lesions evolving 
simultaneously from erythematous macules to papules, vesicles, pustules, and final crusting 
after about 5 to 7 days. Usually not the entire dermatome is involved. Clinical signs include 
pruritus, paresthesia, dysesthesia or anesthesia. Local lymphadenopathy may be present. 
Haemorrhagic lesions may occur in patients recieving anticoagulants, antiaggregants and 
long-term corticosteroids. Most frequently, thoracic dermatomes are affected (55%), followed 
by regions supplied by the trigeminal nerve (20%), cervical (11%), lumbar (13%) and sacral 
(2%) dermatomes.19 Sometimes, adjacent or non-adjacent multisegmental, and in very rare 
cases bilateral, HZ is observed21. 
Zoster-associated pain (ZAP) includes the entire pain spectrum of HZ with three 
distinguishable phases: acute pain phase (up to 30 days), subacute pain phase (30-90 days 
after rash healing) and post herpetic neuralgia (PHN, pain for more than 90 days after the 
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onset of rash)22. A prodromal phase as part of acute ZAP, with an onset of pain or 
dysaesthesia prior to visible symptoms of HZ, may additionally be distinguished23. In the 
prodromal phase of HZ, pain is present in about 70-90% of the cases and can be observed 
two to 18 days before the appearance of skin lesions, often leading to a wide array of 
erroneous diagnoses, according to the anatomical site of VZV reactivation, including 
myocardial infarction, cholecystitis, etc.24, 25 Pain quality is often described as a ‘burning’, 
‘sharp’, ‘stabbing’, ‘pulsating’ localized pain and at times accompanied by an unpleasantness 
to stroke or light touch. 
The clinical diagnosis of HZ is easy in the presence of an asymmetrical (unilateral), 
unidermatomal rash of grouped vesicles on an erythematous background, associated with 
prodromal and ZAP24 (Table 2). However, polymerase chain reaction (PCR) studies 
demonstrated that the differential diagnosis with zosteriform herpes simplex virus (HSV) 
infections is erroneous in up to 4-20%.26-29 Therefore laboratory testing is suggested in the 
event of diagnostic uncertainty, particularly in case of HZ of the face and genital areas, as 
these areas are the natural sites for recurrent labial and genital herpes, respectively (Table 
2). Atypical mucocutaneous forms are clinically difficult to diagnose, especially when the 
typical zosteriform distribution is lacking. Other zosteriform dermatoses are to be excluded.30 
Table 2: Health question 1, Diagnostic means, Recommendations #1 and #2 
Recommendation Supporting literature Strength Consensus 
#1 In the case of classical unilateral HZ of the thoracic or lumbar 
dermatomes, we recommend clinical diagnosis without 
laboratory diagnostic confirmation. 
Clinical 
consensus ↑↑ ≥ 90 % 
#2 In cases of diagnostic uncertainty, we suggest using viral 
antigen detection or molecular based techniques (PCR), 
particularly in order to distinguish HZ of the face and genital 
areas from zosteriform HSV-infection. 
Clinical 
consensus, 
Kalman et al. 
198626, 
Yamamoto et 
al. 199429, 
Tyring et al. 
199528, 
Rubben et al. 
199727 
↑ ≥ 90 % 
 
 
Molecular techniques  
PCR is the most sensitive method reaching 95 to 100% sensitivity and specificity31, 32 (Table 
3). A vesicle fluid swab can be performed on an ulcerated or oozing lesion or after deroofing 
a vesicular lesion. VZV can also be recovered by PCR from lesion crusts or by swabbing the 
dried lesion with a moistened swab. Salivary fluid or buccal swabs taken during the acute 
rash are tested positive for VZV-DNA in up to 100% of cases33 and may persist positive for 
weeks.34 Other clinical specimens approriate for PCR testing are biopsies, cerebro spinal 
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fluid (CSF), intra-ocular fluids and blood samples for the detection of VZV viremia35. Real 
time PCR, ideally in combination with serology on paired serum and CSF/intra-ocular fluid in 
patients sampled at >2-3 weeks after onset of disease, is the method of choice for diagnosis 
of HZ with cerebral and ocular complications or other organ involvements.36-38 Quantitative 
measurement of VZV-DNA in the CSF and blood may serve as a predictor of the outcome of 
the disease.36, 38, 39 Multiplex PCR enables the simultaneous detection of VZV and other DNA 
viruses (e.g. HSV-1, HSV-2) in one clinical sample.40, 41 It has to be considered that VZV can 
also reactivate intermittently, often sub-clinically, shedding small amounts of virus without 
causing symptoms.33, 35, 42  
Antigen detection  
Using monoclonal antibodies directed against different VZV proteins renders direct 
fluorescent antibody (DFA) or immunohistochemistry (IHC) testing type-specific. The 
sensitivity and specificity of DFA were reported to be 82% to 98 % and 76% to 94%, 
respectively31, 32, 43, 44 (Table 3). When IHC was applied to Tzanck smears of HZ patients, the 
diagnostic accuracy reached 92.3% (immediate early protein 63 (IE63)) and 94.9% 
(glycoprotein E (gE)) with a 100% specificity.45 This study also revealed that the anti-gE 
antibody seems to be the ideal diagnostic tool. In fact, gE is the major glycoprotein of the 
VZV envelope. The DFA and IHC on Tzanck smears are easy to perform within 1 to 3 hours. 
Limitations are the need for experienced staff for the microscopic evaluation and that the 
scrapings and swabs on the slide must contain sufficient numbers of cells.  
Table 3: Health question 1, Diagnostic means, Recommendation #3 
Recommendation Supporting literature Strength Consensus 
#3 We recommend using PCR as technique to identify VZV in 
sampled material, or antigen detection based methods as 
valuable alternatives. 
Sauerbrei et al. 
199931 
Wilson et al. 
201232 
↑↑ ≥ 90 % 
 
 
Antibody detection 
Serology for detecting VZV-specific IgM, IgG and IgA responses by ELISA, EIA, electron and 
immunogoldelectron microscopy as well as histochemical staining without IHC on smears are 
only recommended for HZ diagnosis in specific situations.   
Viral culture 
Viral culture on human diploid lung fibroblast (W-38 or MRC-5) or on human retinal pigment 
epithelial (RPE) cells permits isolation of the virus and has long been considered the gold 
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standard. However, due to the instability of this highly cell-associated herpesvirus, sensitivity 
ranges from 20 - 80% in optimal conditions.31, 41, 44, 46, 47 VZV-induced cytopathic effects 
usually appear after 3 to 8 days (mean: 7,5 days).46 Shell vial cultures permit detection of 
specific viral antigens even before the appearance of the cytopathic effects.48 Viral culture 
remains a useful approach when a viable virus isolate is needed for testing drug sensitivity or 
molecular characterization. 
 
Specific situations 
Ophthalmic HZ is associated with a high rate of complications, especially when the 
nasociliary division of the ophthalmic nerve is involved, as evidenced by Hutchinson’s sign, 
namely papulovesicular lesions on the side and top of the nose.  Significant complications 
include acute or delayed  keratitis, uveitis, conjunctivitis, scleritis, eyelid retraction, 
oculomotor palsies, paralytic ptosis, secondary glaucoma, optic neuritis or even acute retinal 
necrosis (ARN) with the risk of bilateral blindness.49, 50 Ocular involvement may occur with 
delayed onset of more than 4 weeks. Keratitis and uveitis recur in approximately 10% of HZ 
ophthalmicus patients and increase the risk of  visual impairment.50, 51  Since (intra)ocular 
involvement is common and may not be noted by general inspection, the panel recommends 
to ask for ophthalmologist advice in the event of facial HZ with ocular involvement (Table 4), 
in order to determine the treatment strategy and necessity for ophthalmologist reassessment. 
The most accurate method to confirm the diagnosis of intraocular involvement is to 
demonstrate the presence of VZV DNA or intraocular production of anti-VZV antibodies.52, 53 
Table 4: Health question 1, Diagnostic means, Recommendation #4 
Recommendation Supporting literature Strength Consensus 
#4 We recommend seeking for ophthalmologist advice in the 
event of HZ ophthalmicus in order to exclude complicated 
courses. 
Yawn et al. 
201350 ↑↑ ≥ 90 % 
 
 
HZ oticus typically presents as pain in the ear canal, possibly accompanied by an auricular 
vesicular rash54. Ramsey-Hunt syndrome is defined as involvement of the facial or auditory 
nerves, with ipsilateral facial palsy, HZ lesions of the external ear, tympanic membrane 
and/or the anterior two-thirds of the tongue55-57. Complications are vertigo, tinnitus, otalgia, 
dysgeusia, osteonecrosis and deafness.58 No specific recommendation for enhanced 
diagnostic means is proposed in the case of HZ oticus, but due to the risk of severe 
complications58, it is recommended to seek advice of an otorhinolaryngologist, especially in 
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the case of involvement of the facial or auditory nerves (Table 5), in order to determine the 
treatment strategy and necessity for otorhinolaryngologist reassessment. 
Table 5: Health question 1, Diagnostic means, Recommendation #5 
Recommendation Supporting literature Strength Consensus 
#5 We recommend seeking advice of an otorhinolaryngologist in 
the event of HZ oticus, especially in the case of involvement of 
the facial and/or auditory nerves. 
Clinical 
consensus, 
Shin et al. 
201558 
↑↑ ≥ 90 % 
 
 
HZ sine herpete is defined as the presence of unilateral dermatomal pain without cutaneous 
lesions in patients with virologic and/or serologic evidence of VZV infection. The most 
accurate method to confirm the diagnosis is to demonstrate an increase in the blood of anti-
VZV IgG and IgM. The identification of specific serum IgA may be of additional value.59, 60 In 
cases of HZ sine herpete with facial palsy, VZV-DNA may be detected in oropharyngeal 
swabs two to four days after the onset of facial palsy using PCR61 (Table 6). 
Table 6: Health question 1, Diagnostic means, Recommendation #6 
Recommendation Supporting literature Strength Consensus 
#6 In the case of suspected HZ sine herpete, we suggest 
searching for blood increase of anti-VZV IgG and IgM.* In the 
case of suspected HZ sine herpete with facial palsy, we 
suggest VZV-DNA detection on oropharyngeal swabs 2 to 4 
days after the onset of facial palsy. 
 
*The identification of serum anti-VZV IgA may be helpful for the 
diagnosis of herpes zoster sine herpete and has been suggested by 
one member of the expert panel. 
Ikeda et al. 
199660, Hadar 
et al. 199059, 
Furuta et al. 
199761 
↑ ≥ 90 % 
 
 
Atypical cutaneous presentations of HZ have been described, including verrucous,62 
lichenoid,63 follicular,64, 65 granulomatous HZ66 and granulomatous angeitis.67-71 In the event of 
atypical cutaneous manifestations, a diagnostic skin biopsy is advocated to detect the virus 
using immunohistochemistry, in situ hybridization or PCR. If atypical cutaneous 
manifestations are ulcerated or oozing, a swab may be performed for antigen detection/PCR 
testing (Table 7).  
Table 7: Health question 1, Diagnostic means, Recommendation #7 
Recommendation Supporting literature Strength Consensus 
#7 For atypical mucocutaneous manifestations including lichenoid, 
verrucous, granulomatous and follicular lesions, we 
recommend a diagnostic biopsy for lesions without ulceration 
and a swab when ulceration is present. 
Clinical 
consensus ↑↑ ≥ 90 % 
 
 
Childhood HZ is quite similar to adult HZ, but ZAP is absent in the majority of cases.72-74  
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Recurrent HZ is not uncommon and was observed in 6,2% over a period of 8 years rising to 
30% in patients with concommittant immunosuppression.75  
 
Complicated courses of HZ 
Cutaneous complications of HZ include hypo- or hyperpigmentation, scarring, keloid 
formation and bacterial superinfection, clearly related to the severity of the skin lesions.   
The most frequent sequela of acute HZ is PHN, usually defined as pain persisting three 
months or more after resolution of the cutaneous HZ lesions. The incidence and severity of 
PHN increase with age, particularly affecting those aged 50 years or more.76-78 Individuals 
affected by ophthalmic HZ with keratitis or intraocular inflammation were found to be at 
higher risk for PHN.76 A scoring system for the calculation of the individual PHN risk, 
including the following risk factors has been proposed: female gender, age > 50 years, 
number of lesions > 50, cranial / sacral localisation, haemorrhagic lesions, and prodromal 
dermatomal pain.79 In the majority of cases, PHN  progressively  improves and after one year 
only 1-2% of the patients still experience pain.  
HZ can be more severe and extensive, with disseminated and/or confluent involvement of 
the skin. Furthermore, VZV can spread from the skin or through VZV viremia to other organs, 
with a spectrum of single organ VZV involvement, and can be associated with anything from 
a good prognosis to multisystemic organ failure, so called visceral zoster, which is frequently 
fatal despite high-dose intravenous antiviral treatment.80, 81  
Patients at risk of severe HZ and hence at increased risk for cutaneous and/or systemic 
dissemination as well as more severe PHN can be identified by a series of risk factors, such 
as age older than 50 years76, 77, 82, moderate to severe prodromal or acute pain76, 
immunosuppression77, 82-84 including cancer, haemopathies, HIV infected, solid organ and 
bone marrow transplant recipients, and other patients receiving immunosuppressive 
therapies. Certain clinical findings at an early stage of HZ identify patients at higer risk of 
complications.  These include the presence of satellite lesions (aberrant vesicles)85, severe 
rash and/or involvement of multiple dermatomes or multisegmental HZ86, simultaneous 
presence of lesions in different developmental stages, altered general status, and meningeal 
or other neurological signs and symptoms. The panel recommends to search for these signs 
in patients presenting with HZ (Table 8). Table 9 gives an overview of risk factors for 
complicated courses of HZ. 
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Table 8: Health question 1, Diagnostic means, Recommendations # 8 and #9 
Recommendation Supporting literature Strength Consensus 
#8 We recommend searching for 
haemorrhagic/necrotizing lesions, satellite lesions 
(aberrant vesicles), multisegmental or generalized 
cutaneous involvement, simultaneous presence of 
lesions in different developmental stages, altered 
general status and meningeal signs in every patient 
who presents with HZ. 
El Hayderi et al. 
201585 ; Nagasako et 
al. 200286 ; clinical 
consensus 
↑↑ ≥ 90 % 
#9 We recommend increased surveillance for complicated 
courses of HZ in patients at an age older than 50 years, 
concommitant immunosuppression (including cancer, 
haemopathies, HIV seropositivity, solid organ and bone 
marrow transplant recipients, and immunosuppressive 
therapies), concomittant severe atopic 
dermatitis/eczema, and in patients with HZ of the head / 
neck area. 
Clinical consensus; 
Jemsek et al. 198382; 
Forbes et al 201676; 
Hillebrand et al. 
201577; 
DeLaBlanchardiere et 
al. 200083; Hughes et 
al 199384; Yawn et al. 
20137; Shin et al 
201558 
↑↑ ≥ 90 % 
 
 
Table 9: Risk factors for complicated courses of Herpes zoster 
Risk factor Increased risk of… 
HZ of the head and / or neck 
area 
HZ ophthalmicus Intraocular involvement and 
complications49-51 
PHN76, 79 
Neurological involvement / 
sequelae87 
HZ oticus Vestibulo-cochlear sequalae58 
Neurological involvement / 
sequelae87 
HZ in other facial or cervical 
dermatomes 
Neurological involvement / 
sequelae87 
HZ with moderate to severe prodromal or acute zoster-associated 
pain 
PHN76, 79 
HZ with severe rash and / or 
signs of cutaneous 
dissemination 
Aberrant vesicles PHN76, 79 
Cutaneous dissemination85 
Neurological involvement / 
sequelae82  
Visceral dissemination 
Hemorrhagic and / or 
necrotizing lesions 
Involvement of the mucuous 
membranes 
Multisegmental HZ 
Generalized HZ 
HZ with signs of involvement of the central nervous system Neurological sequelae 
Complicated, fatal course 
HZ with signs of visceral involvement Complicated, fatal course 
HZ in advanced age PHN76, 77, 79 
Cutaneous dissemination77 
Neurological involvement / 
sequelae77, 82 
HZ in immunocompromised patients (including cancer, 
haemopathies, HIV infected, solid organ and bone marrow 
transplant recipients, and other patients receiving 
immunosuppressive therapies) 
Recurrent HZ75 
Atypical manifestation 
Cutaneous, neurological and / 
or visceral dissemination77, 82-85 
Persisting HZ / aciclovir 
resistant HZ88, 89 
HZ in patients with severe predisposing skin diseases (e.g. atopic 
dermatitis) 
Cutaneous dissemination 
 
 13 
European consensus-based (S2k) Guideline on the Management of Herpes zoster  
– guided by the EDF in cooperation with EADV [Part 1: Diagnosis] 
 
 
Asymptomatic involvement of the central nervous system (CNS) is frequently reproducible in 
patients with HZ of the head/neck area.87 Among others, encephalitis, meningoencephalitis, 
myelitis, cerebellitis, cerebrovascular disease, radiculitis and Guillan-Barré syndrome have 
been reported as CNS manifestations associated with HZ, predominantly in 
immunocompromised patients.70, 82-84 Symptomatic motor nerve paralysis is not a frequent 
complication of HZ, and is usually transitory ; it may lead to paralysis of diaphragm paralysis, 
shoulder, bladder, limb paresis etc., depending on the anatomical site affected by HZ.  
Neurological complications of HZ are rare, but nevertheless it is recommended to check for 
meningeal signs (Table 8). In the case of acute focal neurological dysfunction or other 
neurological signs and symptoms in HZ patients, further workup involving a neurologist is 
recommended (Table 10). In any event, an MRI should be performed if there are any long-
term sequelae. Furthermore, herpetic encephalitis and meningitis (both HSV- and VZV-
induced) appear a risk factor for the sight-threatening ARN.90 Since treatment may improve 
the outcome at least for the second eye, it is relevant for clinicians to be aware of this 
association. 
Table 10: Health question 1, Diagnostic means, Recommendation #10 
Recommendation Supporting literature Strength Consensus 
#10 In case of neurological symptoms and/or signs in the 
event of HZ, we recommend seeking for neurologist 
advice and performing a lumbar puncture. An acute 
MRI is recommended if there are any neurological 
signs outside the VII and VIII the nerves (e.g. a VI 
palsy) or if there is any change in the level of 
consciousness. A CT Scan is suggested when there is 
a loss of more than 2 points on the Glasgow Coma 
Scale score. 
Clinical consensus ↑↑ ≥ 90 % 
 
HZ was shown to be an independent risk factor for vascular disease, particularly for stroke, 
transient ischaemic attack, stroke and myocardial infarction91-93. We therefore suggest to be 
particularly attent towards acute symptoms of cardio- and cerebrovascular events (Table 11).  
Table 11: Health question 1, Diagnostic means, Recommendation #11 
Recommendation Supporting literature Strength Consensus 
#11 We suggest paying particular attention towards 
symptoms of acute cardio- and cerebrovascular events 
in patients who present with HZ. 
Breuer et al. 201491 ; 
Minassian et al. 
201593 ; Langan et al. 
201492 
↑ ≥ 90 % 
 
Systemic VZV dissemination in immunocompromised patients with HZ is the most severe, 
but fortunately rare, acute complication. It is recommended that clinicians exclude potential 
associated complications such as pneumonitis, hepatitis, disseminated intravascular 
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coagulation, CNS signs in patients with HZ and acute severely altered general status (Table 
12). 
Table 12: Health question 1, Diagnostic means, Recommendation #12 
Recommendation Supporting literature Strength Consensus 
#12 In patients who present with HZ and severely altered 
general status, we recommend searching for 
associated complications such as pneumonitis, 
hepatitis, disseminated intravascular coagulation, or 
involvement of the central nervous system. 
Clinical consensus ↑↑ ≥ 90 % 
 
 
Searching for (occult) risk factors 
HZ is considered an indicator condition for HIV infection, and in various settings an increased 
prevalence of HIV seropositivity could be demonstrated for HZ patients, particularly in the 
presence of multidermatomal or recurrent HZ and in the presence of other risk factors for HIV 
seropositivity94-96. In younger patients (possible cut-off 50 years of age) exhibiting HZ, 
particularly in case of widespread multidermatomal or recurrent HZ, simultaneous lesions in 
different disease stages, or presence of other risk factors for HIV seropositivity, it is 
recommended to test for HIV infection (Table 13).   
Table 13: Health question 1, Diagnostic means, Recommendation #13 
Recommendation Supporting literature Strength Consensus 
#13 We recommend testing for HIV infection in younger patients 
(possible cut-off 50 years of age or younger) exhibiting 
widespread multidermatomal or recurrent HZ, particularly 
when lesions are simultaneously present in different disease 
stages and/or when other risk factors for HIV seropositivity are 
present. 
Sullivan et al. 
201396; 
Naveen et al. 
201194; 
Sharvadze et 
al. 200695 
↑↑ ≥ 90 % 
 
Searching for occult cancer in patients with HZ remains debated. In a large cohort of HZ 
patients, subsequent incidence rates of various types of cancer were analysed. Standardized 
incidence rates were not increased in this sample.97 In contrast, a retrospective controlled 
cohort study found a hazard ratio for the risk of cancer following HZ of 2.42 (95% confidence 
interval 2.21 – 2.66).98 Based on these controversial findings and on clinical consensus, the 
panel does not recommend investigations for occult cancer solely based on the occurrence 
of HZ (Table 14). 
Table 14: Health question 1, Diagnostic means, Recommendation #14 
Recommendation Supporting literature Strength Consensus 
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#14 We suggest against investigations for cancer only based on 
the occurrence of HZ. 
Clinical 
consensus; 
Cotton et al. 
201398; Wang 
et al. 201297 
↓ ≥ 90 % 
 
 
Other specific situations 
Clinical resistance of VZV infections to aciclovir has been defined as a treatment failure after 
antiviral drug therapy for at least 10 to 21 days88, 89, and particularly observed in patients 
presenting verrucous VZV infections62 (Table 15). Phenotypical assessment of aciclovir 
resistance in-vitro has been considered the gold standard for resistance testing of VZV, but it 
is not always feasible and VZV isolation in cell culture has low sensitivity. VZV genotyping is 
faster and may also provide information on the emergence of aciclovir resistant variants 
during long-term aciclovir treatment. However, in contrast to HSV,99 the natural and aciclovir 
resistance associated polymorphisms of VZV TK and DNA Pol are incomplete and not yet 
applicable for diagnostic purposes.89, 100-102 VZV genotyping is restricted to specialized 
laboratories (Table 15). 
Table 15: Health question 1, Diagnostic means, Recommendations #15 and #16 
Recommendation Supporting literature Strength Consensus 
#15 We recommend suspecting clinical resistance of VZV 
infections in case of drug therapy failure after 10 to 21 days, 
particularly in patients presenting with verrucous VZV 
infections. 
Safrin et al 
199188, Saint-
Léger et al. 
200189, 
Wauters et al. 
201262 
↑↑ ≥ 90 % 
#16 We suggest that VZV genotyping could be used as technique 
to provide information on the appearance of aciclovir or other 
antiviral resistant variants. 
Boivin et al. 
1994102, Saint-
Léger et al. 
200189, 
Sauerbrei et al. 
2011101, 
Brunnemann et 
al. 2015100 
↑ ≥ 90 % 
 
It is suggested to confirm whether HZ and any eventual complications occurring in 
vaccinated patients are due to the vaccine strain103, 104 by PCR or sequencing if this is 
available (Table 16).  Sequencing the viral genome can also exclude recombination.105     
Table 16: Health question 1, Diagnostic means, Recommendation #17 
Recommendation Supporting literature Strength Consensus 
#17 Where available, we suggest to confirm whether HZ in Depledge et al. ↑ ≥ 90 % 
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vaccinated patients is due to the vaccine strain by sequencing.   2014105, Costa 
et al. 2016104 
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